LINDSAY BURT: Open Payments
NPI 1730837691 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$931 in 47 payments from 15 companies in 2025. Trend: 2023 $1,207 · 2024 $938 · 2025 $931
Food & beverage: $931
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $213 |
| Astellas Pharma US Inc | 5 | $125 |
| ABBVIE INC. | 6 | $120 |
| Lilly USA, LLC | 4 | $99 |
| Axsome Therapeutics, Inc. | 3 | $86 |
| PFIZER INC. | 5 | $86 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Boston Scientific Corporation | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $22 |
Products named: Veozah, VRAYLAR, Wegovy, PREVNAR 20, MOUNJARO, Auvelity, ZEPBOUND, REXULTI.
Industry payments across TX — which companies pay providers there.
